Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
株式のランク #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
株価
$59.43
時価総額
$121.03B
変化(1日)
0.83%
変化(1年)
0.90%
US
取引 Bristol-Myers Squibb Company (BMY)

カテゴリー

Bristol-Myers Squibb Company(BMY)のP/S比率
March 2026 時点のP/S比率 TTM: 2.50
Bristol-Myers Squibb Company の最新の財務報告および株価によると、現在のP/S比率(TTM)は 2.50 です。2024 年末時点でのP/S比率は 2.37 でした。
Bristol-Myers Squibb Company の P/S 比率の履歴(2000 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 2.50 9.50%
2025 2.28 -3.76%
2024 2.37 0.63%
2023 2.36 -28.95%
2022 3.32 11.21%
2021 2.99 -9.37%
2020 3.29 -21.30%
2019 4.19 11.26%
2018 3.76 -22.46%
2017 4.85 -3.48%
2016 5.03 -27.41%
2015 6.92 12.42%
2014 6.16 15.51%
2013 5.33 72.66%
2012 3.09 9.53%
2011 2.82 21.13%
2010 2.33 -12.15%
2009 2.65 18.75%
2008 2.23 -17.35%
2007 2.70 -6.23%
2006 2.88 23.31%
2005 2.34 -9.03%
2004 2.57 -3.17%
2003 2.65 3.91%
2002 2.55 -49.91%
2001 5.09 -32.92%
2000 7.59 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
14.26 471.10%
US
4.96 98.72%
GB
6.18 147.51%
US
6.35 154.40%
US
5.18 107.35%
CH